Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD.
Bottom Line: Triptolide is the major active compound extracted from Tripterygium wilfordii Hook.f., a traditional Chinese medicinal herb that is commonly used to treat inflammatory diseases.We observed enhanced spatial learning performances, and attenuated Aβ production and deposition in the brain.Triptolide also inhibited the processing of amyloidogenic APP, as well as the expression of βAPP-cleaving enzyme-1 (BACE1) both in vivo and in vitro.
Affiliation: Department of Physiology, Department of Neurobiology, Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing 100069, PR China. Beijing Institute for Brain Disorders, Beijing 100069, PR China.Show MeSH
Related in: MedlinePlus
Mentions: According to the behavioral phenotype, we selected 5-month-old 5XFAD mice, which had shown deficits in learning and memory, to assess the therapeutic effects of triptolide (20 μg/kg of body weight, treated for 8 weeks) on the symptomatic AD model. The behavioral performance of mice was determined at 7 months old (Fig. 2A). As shown in Fig. 2B, the escape pathway on the fifth day of training that was adopted by the 5XFAD mice treated with saline in the hidden platform task was more complicated and longer than that used by control mice treated with saline. Importantly, the behavioral impairment could be rescued upon treatment with triptolide. The escape latency of 5XFAD mice to find the hidden platform was longer than that of controls on day 4 and 5 of training, whereas the triptolide-treated 5XFAD mice demonstrated an improved learning ability in the spatial learning task compared with saline-treated 5XFAD mice (Fig. 2C). However, compared with wild-type control mice, both saline- and triptolide-treated 5XFAD mice spent significantly less time in the target quadrant (Fig. 2D) and took more time to find the quadrant that had originally contained the platform (Fig. 2E) during the probe trial, which was performed 24 hours after the last training session in the hidden platform task. This suggests that triptolide prevented the deterioration of learning ability but did not improve the memory retention of 5XFAD mice. Meanwhile, we also monitored the side effects of triptolide (20 μg/kg of body weight intraperitoneally for 8 weeks) on peripheral tissues of these mice and did not find any toxicity in a wide variety of tissues, including the heart, liver, spleen, lung and kidney (supplementary material Fig. S2). Moreover, treatment with triptolide did not affect the body weight of the 5XFAD mice (supplementary material Fig. S3).
Affiliation: Department of Physiology, Department of Neurobiology, Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing 100069, PR China. Beijing Institute for Brain Disorders, Beijing 100069, PR China.